CAL101
Idiopathic Pulmonary Fibrosis (IPF)
Phase 2Active
Key Facts
About Calluna Pharma
Calluna Pharma is a clinical-stage biotech targeting the root causes of inflammation and fibrosis through a novel platform centered on Damage Associated Molecular Pattern (DAMP) proteins. Its lead asset, an anti-S100A4 antibody (CAL101), is in Phase 2 for IPF, with a broader pipeline targeting oxidized phospholipids (oxPLs) for other chronic inflammatory conditions. The company leverages over 30 years of foundational research from its co-founders and has established a key strategic alliance with Eli Lilly, positioning it to address significant unmet medical needs in large and growing markets.
View full company profileTherapeutic Areas
Other Idiopathic Pulmonary Fibrosis (IPF) Drugs
| Drug | Company | Phase |
|---|---|---|
| OATD-01 | Molecure | Phase II |
| FP-020 (BMS-986235) | Foresee Pharmaceuticals | Phase 2 |
| Buloxibutid (C21) | Vicore Pharma | Phase 2b |
| AP02 | Avalyn Pharmaceuticals | Phase 2 |
| Gento-Fibrose Pulmonaire Program | Genoscience Pharma | Preclinical |
| SM001 (alidornase/Tigerase) | SarcoMed USA | Research |
| NLM-001 | Nelum Pharma | Phase 1 |
| GNS-3545 (ROCK2 Inhibitor) | Genosco | Phase 1 |
| TG2 Inhibitor Program | Isterian Biotech | Preclinical |
| Taladegib (ENV-101) | Endeavor BioMedicines | Phase 2b |
| NVP-13 | Velvio | Pre-clinical |
| LASN01 | Lassen Therapeutics | Preclinical |